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unique	 opportunity	 for	 a	 curative	 approach	 restoring	 the	 complex	 feedback	
regulation	 of	 the	 hypothalamic-pituitary-adrenal	 axis.	 	 Here	 we	 generated	
human	 induced	 steroidogenic	 cells	 (hiSCs)	 from	 fibroblasts,	 blood-	 and	 urine-
derived	cells	through	forced	expression	of	Steroidogenic	Factor-1	and	activation	
of	 PKA	 and	 LHRH	 pathways.	 hiSCs	 had	 ultrastructural	 features	 resembling	
steroid-secreting	 cells,	 expressed	 steroidogenic	 enzymes	 and	 secreted	 steroid	
hormones	in	response	to	stimuli.	hiSCs	were	viable	when	transplanted		into	the	
mouse	 kidney	 capsule	 and	 intra-adrenal.	 Importantly,	 the	 hypocortisolism	 of	
hiSCs	derived	from	patients	with	adrenal	insufficiency	due	to	congenital	adrenal	
hyperplasia	 was	 rescued	 by	 expressing	 the	 wild-type	 version	 of	 the	 defective	
disease-causing	 enzymes.	 Our	 study	 provides	 an	 effective	 tool	 with	 many	
potential	 applications	 to	 study	 adrenal	 pathobiology	 in	 a	 personalized	manner	
and	opens	venues	for	the	development	of	precision	therapies.	
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under	 the	 control	 of	 adrenocorticotropic	 hormone	 (ACTH),	 secreted	 by	 the	
anterior	pituitary	gland,	and	mineralocorticoids	under	the	control	of	 the	renin-
angiotensin	 system.	 Glucocorticoids	 affect	 carbohydrate	 metabolism	 and	
mediate	the	mammalian	stress	response,	while	mineralocorticoids	control	blood	
volume	 and	 salt	 homeostasis.	 	 Primary	 or	 secondary	adrenal	 insufficiency	 (AI)	
results	 from	 adrenal	 failure	 or	 impairment	 of	 the	 hypothalamic-pituitary	 axis,	
respectively.	 In	 both	 cases,	 the	 cortex	 fails	 to	 secrete	 sufficient	 amounts	 of	
glucocorticoids	 and	 adrenal	 androgens,	 but	 in	 primary	 AI	 the	 clinical	
consequences	of	aldosterone	deficiency	make	this	a	more	 lethal	condition.	 	The	
most	 frequent	 cause	 of	 primary	 AI	 is	 autosomal	 recessive	 congenital	 adrenal	
hyperplasia	 (CAH),	 which	 results	 from	 defects	 in	 enzymes	 involved	 in	 steroid	
biosynthesis	 (Merke	 and	 Bornstein,	 2005).	 Patients	 with	 AI	 need	 life-long	
management	 with	 exogenous	 steroids:	 this	 can	 be	 challenging	 as	 no	 drug	
suitably	mimics	the	diurnal	pattern	of	cortisol,	and	objective	variables	measuring	
the	 quality	 of	 replacement	 therapy	 are	 lacking.	 Fine-tuning	 of	 replacement	
therapy	 leaves	only	a	narrow	margin	 for	 improvement:	under-replacement	can	
result	in	severe	impairment	of	well-being	and	incipient	crisis,	while	even	subtle,	
chronic	 over-replacement	 has	 the	 potential	 to	 contribute	 to	 excess	 morbidity	
including	 obesity,	 osteoporosis,	 hypertension	 and	 impaired	 glucose	 tolerance.	
Therefore,	 better	 treatment	 solutions	 are	 urgently	 needed	 (Bornstein	 et	 al.,	
2016).		
The	 ability	 to	 generate	 donor-specific	 and	 functional	 adrenocortical-like	 cells	
would	 facilitate	 i)	 the	 next	 generation	 of	 cell-based	 treatments	 for	 AI;	 ii)	 the	
modelling	 of	 adrenal	 specific	 diseases	 and	 iii)	 the	 testing	 of	 personalised	
interventions	on	cells	derived	from	patients.		
Cells	 with	 an	 adrenocortical-like	 phenotype	 have	 never	 been	 obtained	 in	 a	
patient-	specific	manner;	moreover	previous	attempts	have	resulted	in	cells	with	
very	 limited	 steroidogenic	 potential	 (Crawford	 et	 al.,	 1997),	 or	 have	 employed	
lines	of	 embryonic	 stem	cells	 (Jadhav	and	Jameson,	2011;	Yazawa	et	 al.,	 2011),	
mesenchymal	 stem	cells	 (Gondo	et	 al.,	 2004,	2008;	Mazilu	and	McCabe,	2011a;	
Tanaka	 et	 al.,	 2007;	 Wei	 et	 al.,	 2012;	 Yazawa	 et	 al.,	 2006,	 2009,	 2010)	 and	
induced	pluripotent	stem	cells	(iPSCs)	(Sonoyama	et	al.,	2012).	The	prerequisite	
of	all	these	studies	was	the	forced	expression	of	Steroidogenic	Factor-1	(SF1),	a	
master	 regulator	 of	 adrenogonadal	 development/function	 and	 encoded	 by	
nuclear	receptor	subfamily	5,	group	A,	member	1,	NR5A1.	 	SF1	is	a	true	effector	
of	cell	fate	as	it	initiates	a	genetic	program	driving	embryonic	mesenchymal	cells	
towards	 a	 steroidogenic	 phenotype/lineage	 (Schimmer	 and	 White,	 2010)	 and		
SF1	mutations	can	result	in	adrenal	insufficiency	(Achermann	et	al.,	2001).	Other	
than	SF1,	additional	transcription	factors	(TFs),	such	as	Wilms	Tumour	1	(WT1),	
CBP/p300-interacting	 transactivator	 2	 (CITED2),	 pre-B-cell	 leukemia	
transcription	 factor	 1	 (PBX1)	 and	 dosage-sensitive	 sex	 reversal,	 adrenal	
hypoplasia	critical	region,	on	chromosome	X,	gene	1	(DAX1)	have	been	shown	to	





luteinizing	 hormone-releasing	 hormone	 (LHRH),	 easily	 accessible	 sources	 of	
cells	 from	 humans	 (blood,	 skin	 and	 urine)	 resulting	 in	 human	 inducible	
steroidogenic	 cells	 (hiSCs).	 These	 hiSCs	 expressed	 steroidogenic	 enzymes	 and	




cell-based	 treatments	 for	 AI,	 we	 performed	 pilot	 in	 vivo	 experiments	 proving	
viability	 of	 hiSCs	 after	 transplantation	 into	 the	 adrenal	 gland	 and	 under	 the	
kidney	capsule	of	mice.	 These	 experiments	pave	 the	way	 for	 further	 testing	 of	





Primary	 cultures	 of	 human	 urine-derived	 stem	 cells	 (USCs),	 late-outgrowth	
endothelial	 progenitor	 cells	 (L-EPCs)	 and	 fibroblasts	were	 initially	 established	
from	healthy	 donors	 (Fig.	 S1).	 	 As	 L-EPCs	 are	 phenotypically	 indistinguishable	





were	 used	 to	 infect	 human	 primary	 cells.	 The	 vectors	 co-express	 GFP	
bicistronically,	and	contain	a	mammalian	resistance	cassette,	which	was	used	for	
selection	(Fig.	S2A).		Cells	were	transduced	according	to	the	schematic	in	Fig.	1A	
and	 as	 reported	 in	 the	 Methods	 section.	 The	 expression	 of	 the	 steroidogenic	
acute	 regulatory	protein	(STAR)	was	used	as	a	read-out	 for	 initial	experiments;	
STAR	 mediates	 the	 transfer	 of	 cholesterol	 from	 the	 outer	 to	 the	 inner	







BMECs	 (Fig.	 S2B).	 Unlike	 SF1,	 forced	 expression	 of	 the	 other	 TFs	 either	 alone	
(Fig.	1B)	or	in	combination	did	not	induce	STAR	expression	and	neither	did	they	
enhance	 the	 effect	 of	 SF1	 alone	 (Fig.	 1C).	 Lentiviral	 delivery	 of	 SF1	 did	 not	
significantly	 alter	 the	 endogenous	 expression	 levels	 of	 PBX1,	 WT1,	DAX1,	 and	
CITED2,	 except	 WT1	 being	 reduced	 only	 in	 L-EPCs	 (Fig.	 S2B).	 These	 data	
demonstrate	that	SF1	alone	was	able	to	induce	STAR	expression	in	human	cells.	
Interestingly,	upon	SF1	forced-expression,	cells	(irrespective	of	the	source)	had	a	
lower	 proliferation	 rate	 as	 assessed	 by	 expression	 of	 proliferating	 cell	 nuclear	
antigen	 (PCNA)	 and	 direct	 cell	 counting	 (Fig.	 1D),	 and	 became	 proliferation	
arrested	 three	 to	 five	 days	 after	 infection.	 Cells	 with	 this	 seemingly	 terminal	













Morphologically,	 all	 cell	 types	 similarly	underwent	 a	 dramatic	 change	of	 shape	
48-72	hours	post-transduction,	acquiring	an	 irregular	stellate	morphology	with	
concomitant	reduction	of	 the	 cytoplasmic	volume	(Fig.	1G,	 Fig.	S2D,	Movie	S1).	
Despite	 the	 neuronal-like	 morphology,	 absence	 of	 mRNA	 expression	 of	 the	
neuroectoderm	marker	paired	box	gene	6	 	 (PAX6)	 (Zhang	et	 al.,	2010)	and	the	




1H).	 In	 addition,	 reprogrammed	 cells	 had	 an	 increased	 expression	 of	 the	
mitochondrial	 import	 receptor	 subunit	 Translocase	 of	 Outer	 Mitochondrial	
Membrane	20	 (TOM20)	 compared	 to	 controls,	 as	assessed	by	western	 blotting	
(Fig	S2E).	 	Finally,	RT-qPCR	analyses	showed	that	reprogrammed	cells	also	had	
an	 enhanced	 expression	 of	 mitochondrial	 ribosomal	 RNA	 12S	 (Fig.	 S2F).	




Following	 cholesterol	 transfer,	 steroid	 hormones	 are	 produced	 after	 a	 cascade	







(see	 below).	 Fibroblasts,	 L-EPCs	 and	 BMEC	 showed	 an	 identical	 pattern	 of	
steroidogenic	 enzyme	 induction	 (Fig.	 S3A).	 Concomitant	 expression	 of	 SF1,	
PBX1,	 WT1,	 DAX1,	 and	 CITED2	 (5TFs)	 enhanced	 CYP17A1	 and	 HSD3B2	
expression	 while	 they	 decreased	 CYP21A2	 expression	 and	 did	 not	 change	
CYP11A1	expression.	4TFs	without	SF1	had	a	negligible	effect	on	the	expression	
of	 steroidogenic	enzymes	 (Fig.	 S3B).	Moreover,	 the	expression	of	steroidogenic	
enzymes	was	 enhanced	by	br-cAMP	 (Fig.	 S3C),	 as	was	 the	 expression	 of	STAR.		
Reprogrammed	 cells	 did	 not	 express	 the	 testis	 marker	 doublesex	 and	 mab-3	
related	transcription	factor	1	(DMRT1)	and	expressed	the	ovary	marker	estrogen	
receptor	alpha	(ESR1)	at	very	low	levels	(ESR1	 is	also	expressed	in	the	adrenal,	
although	 at	 lower	 level	 compared	 to	 ovary)	 (Fig.	 S3D).	 Moreover,	 luteinizing	
hormone	receptor	(LHR)	was	undetectable	in	control	USCs	and	expressed	a	very	
low	level	in	reprogrammed	cells,	compared	to	the	adrenal	(Fig	S3D).	These	data	
may	 suggest	 a	 preponderance	 of	 adrenocortical-like	 cells	 vs	 gonadal-like	
phenotype	in	reprogrammed	cells.	
Analyses	of	hiSCs	at	the	protein	level	(where	specific	antibodies	were	available)	
confirmed	de	novo	 expression	 of	 STAR,	exogenous	SF1,	 steroidogenic	 enzymes,	
as	 well	 as	 absence	 of	 SULT2A1,	 both	 by	 western	 blot	 (Fig.	 2C)	 and	
immunocytochemistry	 (Fig.	 2D;	 and	 Fig.	 S3E).	 Differentiation	 of	 several	
independent	USC	colonies	from	the	same	donor	or	from	different	donors	(either	
healthy	 or	 with	 congenital	 adrenal	 disease)	 showed	 similar	 reprogramming	
efficiencies	 as	 assessed	 by	 expression	 of	 STAR	protein	 (Fig.	 S3F),	 STAR	 mRNA	
expression,	as	well	as	expression	of	steroidogenic	enzymes	(data	not	shown).		
We	 next	 assessed	 whether	 urine-derived	 hiSCs	 were	 hormone	 producing	 by	
analyzing	 cell	 supernatants	 of	 cells	 8	 days	 after	 reprogramming	 using	 liquid	
chromatography-tandem	mass	spectrometry	(LC-MS/MS).	As	shown	in	Fig.	3A,	a	
very	 significant	 increase	 or	 de	 novo	 production	 of	 steroid	 hormones	 and	
precursors	was	observed	 in	 the	medium	 in	 hiSCs	vs	 control	 cells.	DHEA-S	was	
not	detected,	in	keeping	with	absence	of	SULT2A1	(see	Fig	2	B	and	C).	hiSCs	had	
a	 lower,	 and	 despite	 several	 interventions,	 irreversible	 (Fig.	 S4)	
cortisol/cortisone	 ratio	 compared	 to	 human	 serum	 or	 medium	 from	
adrenocortical	carcinoma	H295R	cells	(Vogeser	et	al.,	2001;	Xing	et	al.,	2011).	
Overall,	 these	 results	 showed	 that	 hiSCs	 secrete	 a	 full	 repertoire	 of	
adrenocortical	 hormones,	 irrespective	 of	 the	 cell	 source,	 as	 hiSCs	 from	
fibroblasts	and	L-EPCs	had	a	similar	steroid	profile	(not	shown).	





or	 in	mock-reprogrammed	cells	 and	produced	at	 low	levels	 in	untreated	hiSCs;	




Recently,	 an	 antagonizing	 effect	 of	 -catenin	 activation	 has	 been	 described	
(promoting	 a	 zona	 glomerulosa	 phenotype)	 as	 opposed	 to	 PKA	 activation	
(promoting	 a	 zona	 fasciculata	 phenotype)	 (Drelon	 et	 al.,	 2016).	 To	 assess	
whether	 the	 activation	 of	 -catenin	 had	 any	 effect	 on	 the	 expression	 of	 zonal-
specific	 markers,	 reprogrammed	 cells	 were	 treated	 with	 recombinant	 WNT4	
(alongside	recombinant	LH);	we	found	no	significant	changes	 in	 the	expression	
of	CYP11B1,	CYP11B2	and	STAR	or	on	cortisol	secretion	(Fig	3D).	Finally,	 it	has	
been	 reported	 that	 the	 luteinizing	 hormone-releasing	 hormone	 (LHRH)	 analog	
[D-Trp6]-LHRH	(Balyura	et	al.,	2015)	and	bombesin	(Malendowicz	et	al.,	1995)	
acutely	 stimulate	 adrenal	 glucocorticoid	 release.	 Both	 LHRH	 and	 bombesin,	
whilst	not	affecting	STAR	mRNA	levels	(Fig.	3E),	significantly	increased	cortisol	
production	 in	 hiSCs;	 however	 only	 LHRH	 significantly	 increased	 the	metabolic	
activity	and	lifespan	of	hiSCs	in	culture	(Fig.	3E).		




hiSCs	 are	 viable	 when	 transplanted	 into	 the	 mouse	 adrenal	 gland	 or	 kidney	
capsule.	
To	test	cell	viability	in	vivo,	hiSCs	from	USCs	were	implanted	in	mice	using	three	
different	 procedures,	 schematized	 in	 Fig.	 S5A:	 firstly,	 via	 ectopic	 implantation	
under	 the	 kidney	 capsule	 as	 free	 cells	 with	 fibrinogen/thrombin	 mixture;	
secondly,	 as	 orthotopic	 (intra-adrenal)	 implants	 with	 fibrinogen/thrombin	




steroidogenic	 enzymes	 such	 as	 CYP11A1,	 were	 observed	 in	 hiSCs	 but	 not	 in	
control	 cells	 (Figs	 4E-L).	 	 Interestingly,	 at	 3	 weeks	 post	 transplantation	 blood	
vessels	 could	 be	 detected	 in	 hiSC-	 but	 not	 control-	 xenografts	 (Figs	 4C,	
quantification	in	D),	suggesting	neovascularization.		
To	 assess	 differentiation	 in	vivo,	 cells	 were	 implanted	 orthotopically	 24	 hours	
post	infection,	at	a	time	when	steroidogenic	enzymes	are	not	expressed	at	either	
mRNA	 or	 protein	 level	 (not	 shown);	 br-cAMP	 and	 LHRH	 were	 also	 omitted.	
Histological	analyses	of	adrenal	gland	explants	after	one	week,	showed	no	signs	
of	fibrosis	or	inflammation	(Figs	4	M	and	N).	To	localize	transplanted	cells	in	the	
context	 of	 host	 adrenocortical	 cells,	 sections	were	 immunostained	with	 a	 GFP	
antibody	 (Fig.	 4O-Q);	 the	 steroidogenic	 potential	 and	 in	vivo	 differentiation	 of	
hiSCs	was	 further	assessed	by	 their	 expression	of	CYP17A1,	 an	 enzyme	 that	 is	
epigenetically	 silenced	 in	 adult	 mice	 (Missaghian	 et	 al.,	 2009);	 we	 observed	
CYP17A1	 staining	 in	 transplanted	 cells	 but	 not	 in	 mouse	 adrenocortical	 cells	
(Fig.	4R-T).		
hiSCs	embedded	in	alginate	and	cultured	 in	vitro	had	the	same	gene	expression	
profile	 and	 hormonal	 secretion	 as	 monolayer	 hiSCs	 (not	 shown);	 however,	
histological	analyses	of	explants	(after	1	week	and	3	weeks)	showed	features	of	
anuclear	 necrosis	 in	 most	 transplanted	 cells	 with	 evident	 signs	 of	 karyolysis	
(nuclear	fading)	and	karyorrhexis	(nuclear	fragmentation)	(Fig.	S5B).	The	same	
was	observed	in	alginate	slabs	embedded	with	control	cells	(not	shown).	These	
experiments	 demonstrate	 viability	 of	 hiSCs	 in	 two	 out	 of	 three	 experimental	
settings	and	pave	 the	way	for	 transplantation	experiments	 on	a	 larger	 scale	 to	
assess	hiSCs	function	in	murine	models	of	AI,	in	which	a	much	greater	number	of	
reprogrammed	cells	are	needed.	However,	hiSCs	generated	from	all	cell	sources	
were	 proliferation-arrested	 (Fig	 1D),	 and	 while	 we	 have	 been	 unable	 to	 find	







carcinomas)	 express	 certain	 steroidogenic	 enzymes	 at	 low	 levels,	 produce	 an	
incomplete	steroid	profile,	and	have	genetic	backgrounds	specific	for	the	donors	
they	 were	 derived	 from.	 Whilst	 animal	 models	 of	 CAH	 have	 been	 generated	
(Bornstein	et	 al.,	 1999;	Mullins	et	 al.,	 2009),	 it	 has	not	been	possible	 to	design	
disease	 models	 involving	 human	 steroidogenic	 cells.	 For	 this	 reason,	 we	
evaluated	the	steroid	profile	of	hiSCs	obtained	from	patients	with	CAH	(Table	1).		
recessive	disorder	caused	by	defects	 in	the	CYP21A2	gene.	Patient	#1	harbored	
one	 of	 the	 most	 common	mutations	 (p.I172N),	 resulting	 in	 a	 simple	 virilizing	
form	of	CAH	and	a	residual	activity	of	the	enzyme	of	1-10%	(Hsu	et	al.,	1996).	LC-
MS/MS	 steroid	 analyses	 of	 parallel	 differentiations	 of	 two	 independent	 USCs	
colonies	 obtained	 from	 patient	 #1	 showed	 an	 accumulation	 of	 metabolites	
upstream	 of	 the	 	 enzyme	 including	 17	 hydroxyprogesterone,	 17	
hydroxypregnenolone	 and	 adrenal	 androgens	 and	 a	 reduction	 of	 those	
downstream,	including	DOC	and	cortisol,	as	compared	to	healthy	donor	controls	
(Fig.	5A).	Lentiviral	delivery	of	wild	type	CYP21A2	significantly	increased	cortisol	
levels	 in	 a	 dose-dependent	 manner	 concomitantly	 to	 a	 reduction	 of	 17-
hydroxyprogesterone,	17-hydroxypregnenolone	and	testosterone	(Patient	#1	in	
Fig.	 5B).	 Furthermore,	 rescue	 of	 cortisol	 hypo-secretion	 was	 successfully	





Donor-	 and	 disease-specific	 steroidogenic	 cells	 as	 surrogates	 for	 disease	
modeling	 have	 been	 lacking	 up	 to	 now.	 More	 significantly,	 their	 use	 could	 be	
exploited	for	the	development	of	cell-based	treatment	modalities	for	AI.		
We	 have	 shown	 that	 the	 use	 of	 a	 single	 cell	 fate	 regulator	 (SF1/NR5A1),	 in	
conjunction	with	 PKA	 and	 LHRH	 signaling,	 can	 stably	 reprogram	 human	 adult	
skin-,	 blood-	 and	urine-derived	cells	 into	hiSCs.	Forced	expression	of	other	key	
TFs	involved	 in	adrenogonadal	differentiation,	alone	or	 in	combination	was	not	
sufficient	 to	 induce	 hiSCs,	 nor	 did	 their	 expression	 with	 SF1	 enhance	
reprogramming.	However,	 given	 that	 there	 is	 endogenous	 expression	 of	DAX1,	
PBX1,	 CITED2	and	WT1	 in	non-reprogrammed	 cells,	 it	 is	 entirely	 possible	 that	
they	participate	 in	 hiSC	 induction	along	with	SF1,	 although	 the	 higher	 dosages	
delivered	by	our	constructs	did	not	improve	reprogramming.	Activation	of	WNT	
pathway	 through	 WNT4	 is	 associated	 with	 zona	 glomerulosa	 differentiation,	
which	 is	prevented	by	PKA	activation	 (Drelon	et	al.,	 2016).	Treatment	of	hiSCs	
with	recombinant	WNT4	did	not	result	in	changes	of	zonal-specific	markers	nor	
cortisol	 secretion;	 it	 is	 possible	 that,	 in	 our	 experimental	 setting,	 forced-
expression	of	SF1	bypasses	key	differentiation	events	occurring	physiologically	
at	 the	 capsule/subcapsular	 region	 during	 the	 normal	 self-renewal/zonal	
specification	of	the	gland.		
Fibroblasts	 are	 the	 preferred	 cell	 substrate	 for	 reprogramming	 but	 more	
recently	 alternative	 cell	 types	 have	 also	 been	 employed:	 USCs	 are	 highly	
expandable,	 have	 self-renewal	 capacity,	 paracrine	 properties,	 and	 multi-






of	 the	 adrenocortical	 and	 nephritic	 primordium,	 which	 make	 them	 an	 ideal	




facilitate	 a	 more	 specific	 adrenocortical	 or	 gonadal	 induction	 during	
reprogramming.	 Gene	 expression	 analyses	 of	 adrenocortical	 and	 gonadal	
markers	already	suggested	that	our	protocol	might	favour	a	more	adrenocortical	
phenotype	(Fig.	S3D).	
The	 functionality	 of	 hiSCs	makes	 them	 an	 unmatched	 tool	 to	 obtain	 surrogate	
adrenocortical	 cells	 for	 in	 vitro	 disease	 modeling.	 With	 this	 in	 mind,	 we	 have	
derived	 hiSCs	 from	 patients	 with	 CAH,	 showing	 an	 altered	 steroid	 profile.	
Importantly,	 the	 decrease	 in	 cortisol	 production	 in	 hiSCs	 derived	 from	 CAH	
patients	 was	 rescued	 upon	 expression	 of	 the	 exogenous	 native	 forms,	
irrespective	of	the	defective	steroidogenic	enzyme.	
USCs-hiSCs	 were	 shown	 to	 be	 viable	 in	 vivo	 when	 transplanted	 into	 mouse	
adrenal	 gland	 tissue,	 and	 successfully	 differentiate	 towards	 an	 adrenal-like	
lineage	within	 the	 adrenal	 tissue	 itself,	 as	 cells	were	 implanted	 24	 hours	 post	
infection	 when	 steroidogenic	 enzymes	 are	 not	 expressed.	 Whether	 the	
surrounding	 adrenal	 tissue	 favours	 differentiation	 remains	 to	 be	 explored,	 as	
well	as	the	long-term	viability/functionality	and	fate	of	transplanted	cells.		hiSCs	
implanted	 under	 the	 mouse	 kidney	 capsule	 maintained	 the	 expression	 of	
steroidogenic	 enzymes	 and	 showed	 well	 vascularized	 tissue	 at	 the	 site	 of	
transplantation	 after	 3	 weeks,	 suggesting	 viability	 of	 those	 cells	 in	 vivo.	
Remarkably,	 vascularization	was	 not	 observed	 in	 control	 implants;	 this	 can	 be	
explained	either	by	the	intrinsic	ability	of	SF1	to	regulate	adrenocortical	vascular	
remodeling	 through	 the	 expression	 of	 angiopoietin-2	 (Ferraz-de-Souza	 et	 al.,	
2011)	 or	 by	 the	 very	 significant	 up-regulation	 of	 the	 potent	 pro-angiogenic	
tetraspartin	CD9	 in	hiSCs	detected	 in	a	proteomic	array	 in	all	cell	sources	 (Fig.	
S7).	 CD9,	 also	 expressed	 in	 the	 normal	 adrenal	 but	 with	 unknown	 function	
(Nakamura	 et	 al.,	 2001),	 exerts	 its	 angiogenic	 action	 via	 exosomes,	where	 it	 is	
abundantly	expressed	(Andreu	and	Yáñez-Mó,	2014).		
Sodium	alginate	has	been	used	as	a	3D	scaffold	for	cell	immobilization/delivery	
in	 tissue	 engineering	 (Bidarra	 et	 al.,	 2014)	 and	 might	 confer	 some	
immunoprotection	 (Llacua	 et	 al.,	 2016).	 However,	 hiSC	 viability	 was	
compromised	 upon	 implantation;	 control	 cells	 were	 also	 negatively	 affected,	
suggesting	 cell-specific	 toxicity	 of	 alginate	 after	 grafting	 in	 our	 system	 (both	
hiSCs	and	control	cells	embedded	in	alginate	were	viable	and	functional	in	vitro).	
Overall,	these	pilot	transplantation	experiments	showed	that	viability	of	hiSCs	is	
affected	 by	 the	 transplantation	 protocol	 employed.	 Longer-term	 experiments	
with	a	yet-to-be	determined	amount	of	cells	would	allow	for	careful	assessment	
of	 i)	 number	 of	 cells	 needed	 to	 be	 able	 to	 detect	 cortisol	 (undetectable	 in	 our	
pilot	experiments)	ii)	time	to	become	fully	functional	iii)	their	viability	long	term	
and	iv)	their	rescuing	potential	in	animal	models	of	AI.	
Novel	 approaches	 to	 treating	AI	 are	 needed	 for	 a	 condition	 in	which	mortality	
rates	 continue	 to	 be	 two-fold	 higher	 than	 the	 background	 population	 despite	
steroid	 replacement	 (Bergthorsdottir	 et	 al.,	 2006).	 	 Though	 newer	 steroid	
formulations	are	being	developed	to	mimic	circadian	rhythm	more	precisely	(e.g.	
Plenadren	 and	 Chronocort),	 replacement	 remains	 inherently	 limited	 in	 its	
responsiveness	 to	 physiological	 need.	 This	 study	 paves	 the	 way	 for	 the	
development	of	alternative	approaches	 to	 treat	AI.	For	example,	hiSCs	could	be	
implanted	 intra-adrenally	 or	 encapsulated	 using	 immunoisolating	 chambers,	
possibly	 following	 gene-editing	 in	 case	 of	 mono/oligogenic	 disorders,	 as	
previously	 utilized	 in	 beta	 cell	 transplantation	 (Desai	 and	 Shea,	 2017).	 To	 this	
end,	 USCs	 have	 recently	 been	 successfully	 gene-edited	 in	 a	 model	 of	 human	













Primary	 cultures	 of	 urine-derived	 stem	 cells	 (USCs),	 fibroblasts	 and	 late-
outgrowth	 endothelial	 cells	 (L-EPCs)	 were	 isolated	 as	 previously	 described	





















Immunoblotting,	 immunocytochemistry	 and	 immunohistochemistry	 were	






















This	 study	 has	 been	 performed	 under	 the	 ethical	 approval	 NHS	 REC	 form	













Statistical	 analysis	 was	 performed	 using	 GraphPad	 Prism	 7	 and	 statistical	
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Fig.	 1.	 Conversion	 of	 human	 urine-derived	 stem	 cells	 into	 steroidogenic	
cells.		







8	 days	 before	 analyses.	 B)	 RT-PCR	 showing	 STAR	 expression	 upon	 forced	
expression	 of	 each	 TF.	 The	 expression	 of	 exogenous	 SF1,	 PBX1,	 WT1,	 DAX1,	
CITED2	was	 assessed	 by	 RT-PCR	using	 primers	 encompassing	 the	 coding-	 and	
vector-	 specific	 regions.	Human	adrenal	 cDNA	was	used	as	positive	 control	 for	
endogenous	 STAR	 expression,	 and	 along	 with	 non-template	 control	 (NTC),	 as	
negative	 control	 for	 exogenous	 TF	 expression.	 C)	 qPCR	 analyses	 of	 STAR	
expression	upon	forced	expression	of	SF1	with	each	TF	(upper	panel)	and	of	SF1	
with	or	without	a	combination	of	TFs	(lower	panel).	D)	Western	blot	analyses	of	





or	without	 the	 indicated	 treatments,	 started	 the	 day	 after	 infection	 for	 7	 days.	
CNT	refers	to	cells	infected	with	empty	control	vector.	F)	RT-qPCR	(upper	panel)	
and	 RT-PCR	 (lower	 panels)	 analyses	 of	 STAR	 and	 SF1	 expression	 after	
reprogramming	USCs	at	different	multiplicity	of	infection	(MOI)	of	SF1	or	empty	
control	 lentiviral	 vector	 (CNT).	 G)	 Morphological	 changes	 upon	 SF1	
overexpression	in	USCs	8	days	post-infection.	Scale	bars	for	panels	=	20	µm. H)	










cells	 were	 treated	 with	 br-cAMP.	 NTC,	 no	 template	 control.	 C)	Western	 blot	
analyses	of	STAR,	SF1,	steroidogenic	enzymes,	SULT2A1	and	GAPDH	expression	
in	 USCs,	 and	 in	 USCs	 infected	 with	 SF1	 or	 control	 lentiviruses	 (mock)	 after	 8	
days.	Human	adrenal	lysate	was	used	as	a	positive	control.	All	cells	were	treated	







in	 controls	 and	 reprogrammed	 USCs	 after	 8	 days.	 C)	 Cortisol	 production	 in	
control	 and	 hiSCs	 treated	with	ACTH	1µM	or	8-br-cAMP	100µM	 for	 8	 days.	D)	
RT-qPCR	 analyses	 of	 STAR,	 CYP11B1,	 CYP11B2	 expression	 in	 controls	 and	
reprogrammed	USCs	treated	with	LH	and	WNT4	for	8	days.	Cortisol	secretion	is	
reported	 in	 the	 right	 panel.	 E)	RT-qPCR	 analyses	 of	 STAR	 expression	 in	 USCs	
treated	with	LHRH,	bombesin	and	ACTH.	Effect	of	[D-Trp6]-LHRH	and	bombesin	






analyses	 of	 cells	 directly	 implanted	 under	 the	 kidney	 capsule	 as	 a	 fibrin	 clot.	
Blood	 vessels	 were	 observed	 to	 develop	 in	 explants	 after	 three	 weeks	 when	
hiSCs	were	implanted	directly	under	the	kidney	capsule	as	a	fibrin	clot	(count	in	
panel	D).	E-H)	Expression	of	 SF1	 in	 controls	(E,	F)	 and	hiSCs	 (G,	H)	 implanted	
directly	under	the	kidney	capsule.	 I-L)	Expression	of	CYP11A1	in	controls	(I,	 J)	
and	 hiSCs	 (K,	 L)	 implanted	 directly	 under	 the	 kidney	 capsule.	 M,	 N)	 H&E	
analyses	of	 a	mouse	adrenal	 gland	transplanted	 for	1	week	with	USCs	 infected	
with	SF1	24	hours	earlier.	hiSCs	can	be	observed	at	the	cortex/medulla	boundary	
(arrow	 in	N).	G-T)	Cells	 transplanted	 into	 the	adrenal	 can	be	visualized	by	 the	
expression	 of	 GFP	 with	 immunohistochemistry	 (O,	 P),	 GFP	 indirect	
immunofluorescence	 (Q),	 or	 by	 their	 expression	 of	 CYP17A1	 via	
immunohistochemistry	(R-T).	 	Arrows	in	O-Q	and	S	point	 to	transplanted	cells.	
CYP17A1	 is	 absent	 in	mouse	 adrenal	 cortex	 (R	 and	T).	 ZG=	 zona	 glomerulosa,	
ZF=	zona	fasciculata.	Scale	bars:	B,	C,	E,	G,	I,	K	=	50	 m;	F,	H,	J,	L,	N,	P,	Q,	S,	T	=	25	
m;	 M,	 O,	 R	 =	 100	 m.	 U-W)	 Development	 of	 an	 inducible	 system	 aimed	 at	
generating	 unlimited	 amounts	 of	 hiSCs.	 U)	 Schematic	 of	 the	 cumate	 vector	
generated	 to	 infect	 USCs.	 In	 repressed	 configuration,	 CymR	 repressor	 strongly	
binds	 to	 the	 cumate	 operator	 site	 (CuO),	 downstream	 of	 the	 CMV5	 promoter.	
When	cumate	is	present	CymR	is	released,	which	enables	transgene	expression.	
V)	USCs	 were	 infected	 with	 the	 cumate	 vector,	 selected	 with	 puromycin,	 and	
then	 treated	 with	 cumate	 or	 vehicle.	 Cells	 underwent	 similar	 morphologic	
changes	to	those	observed	in	Fig.	1G.	Scale	bars	=	50	µm,	for	inset	=	20	µm.	W)	
RT-qPCR	analyses	of	STAR	expression	after	7	days	of	treatment	with	increasing	
concentration	 of	 cumate,	 showing	 induction	 dose-dependently.	 Data	 in	 W	 are	
represented	as	mean	±	SEM,	n	=	3.	See	also	Fig.	S5.	
	
Fig.	 5.	 Characterization	 of	 urine-derived	 hiSCs	 established	 from	 patients	
with	CAH.		
A)	Comparison	of	steroidogenic	profile	of	hiSCs	established	from	patient	#1	with	
CYP21A2	 mutation	 (CAH)	 vs	 healthy	 donors	 (CNT).	 The	 diagram	 on	 the	 left	
shows	 the	 steroidogenic	 pathway	 with	 increased	 metabolites	 in	 patient	 #1	
highlighted	 in	 green	 and	decreases	ones	 in	 red.	B)	 Comparison	of	 cortisol,	17-
hydroxyprogesterone,	17-hydroxypregnenolone	and	testosterone	levels	of	hiSCs	
derived	 from	patient	#1	with	or	without	 restoration	 of	 the	wild-type	 form	21-
OH.	 Cells	were	 infected	with	 two	 increasing	amounts	of	 lentiviral	 particles	 (1x	
and	5x).	C)	 Comparison	of	 cortisol	 levels	of	hiSCs	derived	from	patients	(#2	 to	
#5)	with	several	forms	of	CAH	with	or	without	restoration	of	the	wild-type	form	
of	 the	 corresponding	 steroidogenic	 enzymes.	 RT-PCR	 analyses	 using	 primers	




Table	 1:	 Congenital	 Adrenal	 Hyperplasia	 patients	 enrolled	 in	 this	 study.	
Patient	 #1	 presents	 a	 simple	 virilizing	 form	 of	 CAH	 due	 to	 one	 of	 the	 most	
common	mutations	in	CYP21A2	(p.I172N).	Patient	#2	harbors	a	premature	stop	
codon	 in	 CYP21A2	 at	 glutamine	 319	 (p.Q319*),	 which	 has	 been	 previously	
described	as	pathogenic.	Patient	#3	harbors	a	 frameshift	mutation	 in	 the	STAR	
protein	 (p.	 Thr223fs),	 leading	 to	 disruption	 of	 the	 C-terminal	 START	 domain	
responsible	 for	 cholesterol	 binding	 and	 promotion	 of	 the	 translocation	 of	
cholesterol	 to	 the	 mitochondrial	 inner	 membrane.	 Patient	 #4	 was	 diagnosed	
with	HSD3B2	deficiency	biochemically.	Patient	#5	is	compound	heterozygous	for	
two	 putative	 splicing	 mutations	 in	 the	 CYP11A1	 gene,	 which	 result	 in	 exon	 5	












Patient/donor ID Gene affected DNA Protein 
Patient #1 CYP21A2 c.515T>A p.(Ile172Asn) 
Patient #2 CYP21A2 c.955C>T p.(Gln319Stop) 
Patient #3 STAR c.666delC p.(Thr223Leufs*98) 
Patient #4 HSD3B2 n/a n/a 
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